SCHEMBL10284538

SCHEMBL10284538

CNS(=O)(=O)c1cnccc1-c1nc2cc(C(F)(F)F)cnc2n1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.40
SMN1; SMN2 Q16637 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
ALOX5AP P20292 1/20 0.36
FEN1 P39748 1/20 0.36
PTGS2 P35354 3/20 0.35
LMNA P02545 3/20 0.34
HTT P42858 2/20 0.34
PDE2A O00408 2/20 0.33
SLC40A1 Q9NP59 1/20 0.33
PDE7A Q13946 1/20 0.33
PDE10A Q9Y233 1/20 0.33
PTGS1 P23219 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL116514 0.89 POLB (0.41) POLBPTGS2PDE2APDE7APDE10A
SCHEMBL10284733 0.88 PTGS2 (0.42) POLBPTGS2PDE2APDE7APDE10A
SCHEMBL10284408 0.88 POLB (0.41) POLBMEN1KMT2APTGS2LMNA
SCHEMBL355701 0.87 POLB (0.45) POLBPTGS2PDE2APDE7APDE10A
SCHEMBL13075451 0.86 POLB (0.40) POLBSMN1; SMN2PTGS2LMNAHTT
SCHEMBL357857 0.81 PDE10A (0.48) POLBSMN1; SMN2CYP1A2PTGS2PDE2A
SCHEMBL16612050 0.80 POLB (0.45) POLBPTGS2PDE10APTGS1CYP17A1
SCHEMBL115623 0.80 POLB (0.43) POLBSMN1; SMN2CYP1A2PDE2APDE7A
SCHEMBL4398672 0.80 POLB (0.43) POLBSMN1; SMN2CYP1A2PTGS2PDE2A
SCHEMBL116863 0.80 POLB (0.43) POLBSMN1; SMN2CYP1A2PDE2APDE7A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461181-B2 Fused heterocyclic compound and use thereof SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2013-06-11 US disclosed
US-8273764-B2 Fused heterocyclic compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-09-25 US disclosed
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-07-12 US disclosed
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-01-19 US disclosed
WO-2010125985-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 POLB 4724/4885SMN1; SMN2 1524/4885MEN1 637/4885
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 POLB 4724/4885SMN1; SMN2 1524/4885MEN1 637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.